Loading...
XKRX041830
Market cap204mUSD
Dec 30, Last price  
23,200.00KRW
1D
2.20%
1Q
-6.26%
Jan 2017
-14.07%
Name

InBody Co Ltd

Chart & Performance

D1W1MN
XKRX:041830 chart
P/E
8.23
P/S
1.77
EPS
2,819.01
Div Yield, %
1.29%
Shrs. gr., 5y
-0.69%
Rev. gr., 5y
11.32%
Revenues
170.35b
+6.47%
33,230,296,36036,786,609,02048,940,140,49068,949,097,53079,848,382,29093,253,712,99499,635,442,563117,058,914,069107,122,053,678137,836,961,994160,003,774,093170,351,229,733
Net income
36.72b
+8.60%
5,642,751,3406,194,379,8908,879,319,65017,310,909,05316,986,909,67019,321,817,54119,670,670,94620,428,475,38917,517,981,15034,033,492,96033,815,534,17036,722,823,528
CFO
38.69b
+27.18%
4,355,328,1206,994,673,36010,259,230,79011,178,514,96718,238,319,92518,576,147,00517,704,892,09624,206,000,61928,500,349,90230,350,938,96130,418,862,59438,686,124,120
Dividend
Dec 27, 2023300 KRW/sh
Earnings
Feb 20, 2025

Profile

InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was founded in 1996 and is headquartered in Seoul, South Korea.
URL
https://www.inbody.co.kr/
IPO date
Dec 14, 2000
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
170,351,230
6.47%
160,003,774
16.08%
Cost of revenue
80,475,466
77,400,290
Unusual Expense (Income)
NOPBT
89,875,763
82,603,484
NOPBT Margin
52.76%
51.63%
Operating Taxes
8,036,998
8,664,502
Tax Rate
8.94%
10.49%
NOPAT
81,838,765
73,938,982
Net income
36,722,824
8.60%
33,815,534
-0.64%
Dividends
(3,908,054)
(2,605,369)
Dividend yield
1.18%
0.99%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
2,444,123
2,095,332
Long-term debt
9,716,463
8,602,974
Deferred revenue
1,219,538
Other long-term liabilities
3,534,044
3,119,818
Net debt
(117,706,238)
(92,602,492)
Cash flow
Cash from operating activities
38,686,124
30,418,863
CAPEX
(7,642,367)
(6,016,832)
Cash from investing activities
(32,290,439)
(22,024,520)
Cash from financing activities
(6,161,428)
(5,252,413)
FCF
70,596,321
60,655,373
Balance
Cash
98,967,403
86,605,296
Long term investments
30,899,422
16,695,502
Excess cash
121,349,263
95,300,610
Stockholders' equity
258,217,018
227,581,811
Invested Capital
138,099,950
123,968,458
ROIC
62.46%
63.65%
ROCE
34.64%
37.88%
EV
Common stock shares outstanding
13,027
13,027
Price
25,350.00
25.50%
20,200.00
-12.74%
Market cap
330,230,571
25.50%
263,142,309
-12.74%
EV
213,593,431
171,319,012
EBITDA
95,836,354
87,977,469
EV/EBITDA
2.23
1.95
Interest
329,510
121,987
Interest/NOPBT
0.37%
0.15%